As shown in Figure 8, C and D, we observed reduced progression-free survival (PFS) and overall survival (OS) curves in patients with lung cancer with high expression of SGLT2 and high expression of PD-L1, suggesting that SGLT2 could be utilized as a marker for the expression of PD-L1. This evidence concerns the gene SLC5A2 and lung cancer.